NCT06957938View on ClinicalTrials.gov

Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

April 28, 2025

Primary Completion Date

May 1, 2029

Study Completion Date

May 1, 2031

Conditions
Laryngeal CarcinomaHypopharyngeal Carcinoma
Interventions
DRUG

Neoadjuvant Chemotherapy (NACT)

Neoadjuvant Chemotherapy with paclitaxel (or albumin - bound paclitaxel) and cisplatin

DRUG

Neoadjuvant and maintenance Tislelizumab

Neoadjuvant and maintenance Tislelizumab

RADIATION

Concurrent chemo-radiotherapy (CCRT)

Concurrent chemo-radiotherapy (CCRT), with cisplatin-based chemotherapy

PROCEDURE

Surgery and adjuvant (chemo-)radiotherapy

Definitive surgery, with adjuvant (chemo-)radiotherapy, depending on pathologic findings.

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
collaborator

Sun Yat-sen University Cancer Center (SUSUCC)

UNKNOWN

collaborator

Fujian Cancer Hospital

OTHER_GOV

lead

Fudan University

OTHER